Article thumbnail

Differential effects of periopathogens on host protease inhibitors SLPI, elafin, SCCA1, and SCCA2

By Lei Yin, Bryan Swanson, Jonathan An, Beth M. Hacker, Gary A. Silverman, Beverly A. Dale and Whasun O. Chung
Topics: Original Article
Publisher: CoAction Publishing
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). Acquisition of plasmin activity by Fusobacterium nucleatum subsp. nucleatum and potential contribution to tissue destruction during periodontitis. Infect Immun
  2. (2000). Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease: occurrence and treatment. Periodontology
  3. (2007). Activation of protective responses in oral epithelial cells by Fusobacterium nucleatum and human betadefensin-2.
  4. (2004). Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli.
  5. (2008). Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis-affected gingival tissue.
  6. (2008). an elastase specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.
  7. (1994). and argininespecific proteinases from Porphyromonas gingivalis. Isolation, characterization, and evidence for the existence of complexes with hemagglutinins.
  8. (2005). Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun
  9. (2000). Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor.
  10. (2005). Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer. Infect Immun
  11. (2006). Arginine-specific gingipains from Porphyromonas gingivalis deprive protective functions of secretory leukocyte protease inhibitor in periodontal tissue. Clin Exp Immunol
  12. (2003). Associations between periodontal disease and risk for atherosclerosis, cardiovascular disease, and stroke. A systematic review. Ann Periodontol
  13. (2002). Bacteroides forsythus hemagglutinin is inhibited by N-acetylneuraminyllactose. Oral Microbiol Immunol
  14. (1992). Cathepsin B/L-, elastase-, tryptase-, trypsinand dipeptidyl peptidase IV-like activities in gingival crevicular fluid: a comparison of levels before and after periodontal surgery in chronic periodontitis patients.
  15. (2006). Characterization of proteolytic activities of Fusobacterium nucleatum.
  16. (2003). Cloning of the Tannerella forsythensis (Bacteroides forsythus) siaHI gene and purification of the sialidase enzyme.
  17. (2000). Co-expression of the squamous cell carcinoma antigens 1 and 2 in normal adult human tissues and squamous cell carcinomas.
  18. (2002). Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res
  19. (1982). Collagenolytic activity associated with Bacteroides species and Actinobacillus actinomycetemcomitans.
  20. (2009). Corruption of innate immunity by bacterial proteases.
  21. (2009). Degradation of human and -defensins by culture supernatants of Porphyromonas gingivalis strain 381. J Innate Immun
  22. (2000). Development of specific monoclonal antibodies and a sensitive discriminatory immunoassay for the circulating tumor markers SCCA1 and SCCA2. Clin Chim Acta
  23. (2009). Elafin is specifically inactivated by RgpB from Porphyromonas gingivalis by distinct proteolytic cleavage. Biol Chem
  24. (2006). Elafin prevents lipopolysaccharideinduced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway.
  25. (1999). Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in Effects of periopathogens on host protease inhibitors Citation:
  26. (1998). expression, and sequencing of a cell surface antigen containing a leucine-rich repeat motif from Bacteroides forsythus ATCC 43037. Infect Immun
  27. (1997). expression, and sequencing of a protease gene from
  28. (2001). Gene expression of human squamous cell carcinoma antigens 1 and 2 in human cell lines. Oncol Rep
  29. (2000). Global epidemiology of periodontal diseases: an overview. Periodontology
  30. (1985). Glycosaminoglycan-depolymerizing enzymes produced by anaerobic bacteria isolated from the human mouth. Arch Oral Biol
  31. (2005). Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.
  32. (2006). Inhibition of Porphyromonas gingivalis proteinases (gingipains) by chlorhexidine: synergistic effect of Zn(II). Oral Microbiol Immunol
  33. (2004). Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species. Infect Immun
  34. (2008). Involvement of cysteine protease inhibitors in the defense mechanism against parasites. Med Chem
  35. (1998). Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol Mol Biol Rev
  36. (1998). Local chemokine paralysis, a novel pathogenic mechanism for Porphyromonas gingivalis. Infect Immun
  37. (2006). Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases.
  38. (2000). Microbial etiological agents of destructive periodontal diseases. Periodontology
  39. (1999). Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis.
  40. (2008). Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie
  41. (1998). Neutrophil migration into the gingival sulcus is associated with transepithelial gradients of interleukin-8 and ICAM-1. J Periodontol
  42. (2000). Novel apoptosis-inducing activity in Bacteroides forsythus: a comparative study with three serotypes of Actinobacillus actinomycetemcomitans. Infect Immun
  43. (2005). Periodontal diseases. Lancet
  44. (2001). Periodontal infection and preterm birth: results of a prospective study. J Am Dent Assoc
  45. (2006). Porphyromonas gingivalis epithelial cell interactions in periodontitis.
  46. (1999). Porphyromonas gingivalis gingipains and adhesion to epithelial cells. Infect Immun 2001; 69: 304856. Lei Yin et al. (page number not for citation purpose) Citation:
  47. (2002). Proteolysis of CD14 on human gingival fibroblasts by arginine-specific cysteine proteinases from Porphyromonas gingivalis leading to down-regulation of lipopolysaccharideinduced interleukin-8 production. Infect Immun
  48. (2000). Proteolysis of human monocyte CD14 by cysteine proteinases (gingipains) from Porphyromonas gingivalis leading to lipopolysaccharide hyporesponsiveness.
  49. (2003). Proteolysis of ICAM-1 on human oral epithelial cells by gingipains. J Dent Res
  50. (2000). Proteolytic and hydrolytic enzymes from putative periodontal pathogens: characterization, molecular genetics, effects on host defenses and tissues and detection in gingival crevice fluid. Periodontology
  51. (2009). Proteolytic roles of matrix metalloproteinase (MMP)-13 during progression of chronic periodontitis: initial evidence for MMP-13/MMP-9 activation cascade.
  52. (1992). Purification and characterization of a 50-kDa cysteine proteinase (gingipain) from Porphyromonas gingivalis.
  53. (1994). Purification and characterization of a novel arginine-specific cysteine proteinase (argingipain) involved in the pathogenesis of periodontal disease from the culture supernatant of Porphyromonas gingivalis.
  54. (2001). Rapid detection and quantification of five periodontopathic bacteria by real-time PCR. Microbiol Immunol
  55. (2003). Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun
  56. (2000). Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins.
  57. (2005). Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding.
  58. (2002). Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination.
  59. (2004). Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection.
  60. (2005). Serine proteinase inhibitors in the skin: role in homeostasis and disease. Curr Protein Pept Sci
  61. (2006). Serpin squamous cell carcinoma antigen inhibits UV-induced apoptosis via suppression of c-JUN NH2-terminal kinase.
  62. (2006). SLPI and elafin: one glove, many fingers. Clin Sci (Lond)
  63. (1997). Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase.
  64. (2003). Supernatants of Pseudomonas aeruginosa induce the Pseudomonas-specific antibiotic elafin in human keratinocytes. Exp Dermatol
  65. (2003). The relationship between periodontal diseases and respiratory diseases. Dent Today
  66. (2004). The squamous cell carcinoma antigen 2 inhibits the cysteine proteinase activity of a major mite allergen, Der p 1.
  67. (2000). TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch Dermatol Res
  68. (2000). Virulence factors of Porphyromonas gingivalis. Periodontology